Supply Chain Archives
12/11/2025
Setting the Benchmark for Quality in Cell and Gene Therapy Logistics
Quality in cell and gene therapy (CGT) is the foundation that determines whether a therapy reaches a patient intact and effective. As the industry increasingly scales from early development of CGTs to global commercialization, the margin for error narrows as volume and complexity increase. Standards like ISO 21973 provide a framework, but true industry leadership comes from how those standards are applied. In this, Cryoport Systems is setting that benchmark.
12/09/2025
What is ISO 21973 and Why It Matters for Cell and Gene Therapy
Cell and gene therapies (CGTs) are transforming medicine, but the complexity of these treatments introduces new challenges for supply chain management. Every shipment represents a therapy that could change or save a life, which is a level of responsibility that demands precision and transparency, as well as standards that leave absolutely no room for error. ISO 21973:2020 was created to meet that need.
12/08/2025
Scaling for What’s Next in EMEA
As the advanced therapy medicinal products (ATMP) sector continues to expand across Europe and beyond, the infrastructure supporting these therapies needs to evolve just as quickly. Cryoport Systems is doing exactly that by scaling capabilities, deepening partnerships, and investing in new infrastructure to meet the growing needs of therapy developers.
11/17/2025
How Global Shifts are Reshaping ATMP Logistics Beyond Borders
As advanced therapy medicinal products (ATMPs) continue to gain traction globally, the logistics required to move these therapies across borders are facing unprecedented challenges. From shifting trade policies to regional conflicts and Brexit legacy issues, global events are reshaping how therapies are distributed... and how supply chains must adapt in real time.
10/28/2025
Built or Bought? Why Biotechs are Outsourcing Supply Chain Infrastructure
For companies developing advanced therapy medicinal products (ATMPs), building an in-house end-to-end supply chain may seem like the ultimate sign of maturity. But in today’s resource-constrained market, biotech leaders are increasingly asking themselves whether it’s better to build, or to buy. From startups operating on limited funding to global biopharma players scaling into new markets, outsourcing supply chain infrastructure is becoming more than just a cost saving tactic. By partnering with specialized providers, developers gain instant access to global networks, regulatory expertise and compliance, and technical capabilities that would take years and significant capital to build internally.
10/22/2025
Beyond the Box: Why Shipping System Qualification Matters in Advanced Therapies
For advanced therapy logistics, quality isn’t limited to what happens inside the manufacturing suite. It extends across the entire supply chain, from packaging and transport to the systems that safeguard material integrity at every handoff. Yet one of the most critical (and often underestimated) steps in ensuring integrity is a shipping system qualification.
10/15/2025
The Connected Chain: Why Supply Chain Integration Matters in Advanced Therapy Manufacturing
Contract Development and Manufacturing Organizations (CDMOs) are at the heart of the advanced therapy ecosystem, managing complex, high-stakes programs that demand speed and compliance. As therapies move from early development into clinical trials and through to commercialization, every stage of manufacturing, packaging, biostorage, and final drug delivery need to align perfectly for seamless execution. Yet in many cases, these functions are managed by multiple vendors, each operating in isolation. The result is a fragmented supply chain that increases risk while slowing execution due to layers of operational burden.
10/08/2025
Resilience by Design: Lessons from Real-World Disruption
When it comes to Advanced Therapy Medicinal Products (ATMPs), disruption isn’t an “if,” it’s a “when.” When you’re dealing with unpredictable situations like geopolitical instability, sudden site closures, supply chain bottlenecks, or even weather-related delays, any disruption can potentially jeopardize patient treatments that may be irreplaceable. For sensitive therapies like these with narrow viability windows and strict temperature requirements, even a small deviation in process can have outsized consequences. In her Beyond Biotech podcast interview with Labiotech, Alison Pritchard, VP of Business Development for EMEA at Cryoport Systems, explained why resilience is one of the most critical (but often overlooked) pillars of ATMP delivery.
10/01/2025
